article thumbnail

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

The Pharma Data

Clinical Development Plans and Future Outlook Intellia’s ongoing Phase 3, randomized, double-blind, placebo-controlled HAELO trial is currently assessing the safety and efficacy of lonvo-z at the 50 mg dose in a larger patient population.

article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

We have laid out an ambitious 3-2-1 strategy to get three clinical assets, across two tissue types with a single platform through 2027. We approach this mission with humility, knowing that each step forward is earned through teamwork, learning, an unwavering focus on patients and generating evidence along the way.

RNA 67
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vor, with new CEO, changes course to target autoimmune disease

BioPharma Drive: Drug Pricing

Data from that trial is expected in 2027. “I Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Registered in England and Wales.

Disease 109
article thumbnail

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

BioPharma Drive: Drug Pricing

The company also has $1 billion in senior notes coming due in 2027. The company believes sales in ambulatory patients are likely to annualize at a minimum of $500 million annually through 2027. You can unsubscribe at anytime. as Scientific Advisor From Receptor.AI Informa PLCs registered office is 5 Howick Place, London SW1P 1WG.

Therapies 301
article thumbnail

Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from News roundup Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules Biocryst is offloading part of its business to an Italian drugmaker for $250 million upfront.

Vaccine 130
article thumbnail

CroíValve Secures Horizon Europe EIC Accelerator Funding

The Pharma Data

The EIC Accelerator Programme is part of the broader Horizon Europe 2021–2027 Research and Innovation framework, which provides non-dilutive and equity funding to breakthrough, high-risk innovations with global market potential. These attributes are expected to make the therapy more accessible in routine clinical practice.

article thumbnail

How Many Clinical Trials Are Run by CROs?

Vial

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. That is, how many clinical trials are actually managed by these organizations?